Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone sensors may predict bipolar mood swings before they strike

NCT ID NCT02782910

Disease control Sponsor: Technische Universität Dresden Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests whether continuous smartphone monitoring can detect early warning signs of depression or mania in people with bipolar disorder. Participants use an app that tracks activity and location, and some receive personalized alerts from their doctor when the app detects a potential episode. The goal is to see if this early warning system can delay the next mood episode and reduce hospitalizations compared to monitoring without doctor feedback.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Smartphone-based ambulatory assessment with personalized feedback from a physician
What this could lead to
If it works, this could offer a practical way to catch early warning signs of mood episodes and reduce hospitalizations for people with bipolar disorder.
What could go wrong
The trial is relatively small and the approach depends on patients consistently using the smartphone app. It may not reliably predict episodes for everyone, and the feedback system requires physician availability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

148 people

The number who actually took part.

Started

Jan 2017

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Bipolar Disorders (I/II) * \> 3 affective episodes in 5 years prior to index episode, with one of them being a (hypo)manic episode * Age \> 18 years * Male or female * Inpatients or outpatients * Smartphone usage * Each patient must have a level of understanding sufficient to agree to all tasks required by the protocol. * Patients must be considered reliable. * Each patient must sign an informed consent document prior to enrollment. Exclusion Criteria: * Current substance use disorder (except for tobacco and caffeine), moderate or severe, at enrolment * Borderline personality disorder, antisocial personality disorder * Dementia, organic brain disorders * Unstable/inadequately treated medical illness * Clinically significant cardiac, renal, hepatic, neoplastic or cerebrovascular disease * Any medical condition posing a significant risk regarding adherence to study protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bipolar disorder

Contacts and locations

Locations

  • Department of Psychiatry and Psychotherapy

    Dresden, Saxony, 01307, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.